Sesen Bio is a clinical-stage biopharmaceutical company developing novel therapeutics focused on rare eye diseases. The company's lead product candidate, tinlarebant, is being developed to treat Stargardt disease, a rare inherited retinal degenerative disorder with limited treatment options, and has received orphan drug and breakthrough therapy designations to expedite its regulatory pathway. Sesen Bio intends to pursue regulatory approval and commercialization across major geographic markets including the United States, Europe, China, and Japan, relying entirely on third-party contract manufacturers for production while building internal sales and marketing capabilities to support future product launches.